1. The utility of fluorescence in situ hybridization testing in patients clinically suspected of myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm overlap is limited in the absence of significant morphological dysplasia. (27th August 2020) Authors: Virk, Harpreet; Rana, Sonia; Kapadia, Alpeshkumar B.; Sreedharanunni, Sreejesh; Mallik, Nabhajit; Kumar, Narender; Sharma, Prashant; Naseem, Shano; Sachdeva, Man Updesh Singh; Ahluwalia, Jasmina; Das, Reena; Varma, Neelam; Malhotra, Pankaj Journal: International journal of laboratory hematology Issue: Volume 42:Number 6(2020:Dec.) Page Start: e287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗